Parkash Singh Gill, MD

TitleProfessor of Medicine
InstitutionUniversity of Southern California
Address1441 Eastlake Ave.
Health Sciences Campus
Los Angeles CA 90033
Phone+1 323 865 3909
vCardDownload vCard
    Other Positions
    TitleRenette and Marshall Ezralow Family Chair in Cancer Therapeutics

    Collapse Overview 
    Collapse Overview
    Dr. Gill's primary research interest is in studying novel targets that are expressed both in tumor blood vessels as well as the tumor cell. He has demonstrated the ability to identify and validate novel targets, develop novel target therapeutics and collaborate with clinical investigators to conduct early stage clinical trials.

    Dr. Gill has a strong history of clinical investigations and drug development. His clinical investigations led to the approval of three cancer drugs by the FDA. He also served on the advisory panel for the FDA advisory committee on biologics. Over the past several years his work has focused on the identification of novel cancer and cancer blood vessel targets, validation of the targets in various model systems including genetic mouse models.

    Collapse Research 
    Collapse Research Activities and Funding
    VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    NIH/NCI R01CA079218Jun 1, 1999 - Feb 28, 2011
    Role: Principal Investigator
    NIH/NHLBI R01HL048499May 1, 1992 - Jan 31, 1996
    Role: Principal Investigator
    NIH/NCI R01CA051621Sep 30, 1989 - Jul 31, 1995
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill P. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Adv. 2017 Sep 12; 1(20):1635-1644. PMID: 29296810.
      View in: PubMed
    2. Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. PLoS One. 2017; 12(8):e0183161. PMID: 28817624.
      View in: PubMed
    3. Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill P, Groshen S, Dubeau L, Lee AS. GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice. Proc Natl Acad Sci U S A. 2017 05 16; 114(20):E4020-E4029. PMID: 28461470.
      View in: PubMed
    4. Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, Kuhn P, Gill P, Almeida F, Gill I. Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. BJU Int. 2017 09; 120(3):401-408. PMID: 27981731.
      View in: PubMed
    5. Mundbjerg K, Chopra S, Alemozaffar M, Duymich C, Lakshminarasimhan R, Nichols PW, Aron M, Siegmund KD, Ukimura O, Aron M, Stern M, Gill P, Carpten JD, Ørntoft TF, Sørensen KD, Weisenberger DJ, Jones PA, Duddalwar V, Gill I, Liang G. Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol. 2017 01 12; 18(1):3. PMID: 28081708.
      View in: PubMed
    6. Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill P, Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep. 2016 Dec 12; 6:38792. PMID: 27941840.
      View in: PubMed
    7. Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One. 2016; 11(3):e0152243. PMID: 26998759; PMCID: PMC4801381.
    8. Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill P, Pandey A. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget. 2015 Oct 06; 6(30):29143-60. PMID: 26356563; PMCID: PMC4745717.
    9. Zhou B, Wang H, Liu R, Wang M, Deng H, Giglio BC, Gill P, Shan H, Li Z. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B. Mol Pharm. 2015 Oct 05; 12(10):3527-34. PMID: 26288060.
      View in: PubMed
    10. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481; PMCID: PMC4535951.
    11. Liang M, Adisetiyo H, Li X, Liu X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One. 2015; 10(7):e0131232. PMID: 26196517; PMCID: PMC4510390.
    12. Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ, Gill P, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641. PMID: 26073592; PMCID: PMC4466581.
    13. Wang H, Li D, Liu S, Liu R, Yuan H, Krasnoperov V, Shan H, Conti PS, Gill P, Li Z. Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159. J Nucl Med. 2015 Jun; 56(6):908-13. PMID: 25908833.
      View in: PubMed
    14. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill P, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12. PMID: 25767293; PMCID: PMC5032632.
    15. Ferguson BD, Tretiakova MS, Lingen MW, Gill P, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6. PMID: 25391996; PMCID: PMC4278660.
    16. Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill P, Liu R. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One. 2014; 9(8):e105326. PMID: 25148033; PMCID: PMC4141800.
    17. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill P, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64. PMID: 25136066; PMCID: PMC4167493.
    18. Li D, Liu S, Liu R, Park R, Yu H, Krasnoperov V, Gill P, Li Z, Shan H, Conti PS. Axl-targeted cancer imaging with humanized antibody h173. Mol Imaging Biol. 2014 Aug; 16(4):511-8. PMID: 24424460; PMCID: PMC4183751.
    19. Liu S, Li D, Guo J, Canale N, Li X, Liu R, Krasnoperov V, Gill P, Conti PS, Shan H, Li Z. Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft. Mol Pharm. 2014 Nov 03; 11(11):3974-9. PMID: 24978094; PMCID: PMC4224514.
    20. Li D, Liu S, Liu R, Zhou Y, Park R, Naga K, Krasnoperov V, Gill P, Li Z, Shan H, Conti PS. EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab. Mol Pharm. 2013 Dec 02; 10(12):4527-33. PMID: 24147882; PMCID: PMC3888823.
    21. Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, Krasnoperov V, Dong D, Liu S, Li D, Zhu G, Louie S, Conti PS, Li Z, Lee AS, Gill P. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res. 2013 Dec 15; 19(24):6802-11. PMID: 24048331; PMCID: PMC4151476.
    22. Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill P, Salgia R. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668. PMID: 23844053; PMCID: PMC3699624.
    23. Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill P, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013 May 30; 13:269. PMID: 23721559; PMCID: PMC3671960.
    24. Liu S, Li D, Park R, Liu R, Xia Z, Guo J, Krasnoperov V, Gill P, Li Z, Shan H, Conti PS. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med. 2013 Jul; 54(7):1094-100. PMID: 23667241.
      View in: PubMed
    25. Li D, Liu S, Liu R, Park R, Hughes L, Krasnoperov V, Gill P, Li Z, Shan H, Conti PS. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring. Mol Pharm. 2013 Jan 07; 10(1):329-36. PMID: 23211050; PMCID: PMC3540204.
    26. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94. PMID: 23100466.
      View in: PubMed
    27. He M, Zhang W, Bakken T, Schutten M, Toth Z, Jung JU, Gill P, Cannon M, Gao SJ. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Res. 2012 Jul 15; 72(14):3582-92. PMID: 22593192; PMCID: PMC4034471.
    28. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci. 2012 Jun; 101(6):1969-84. PMID: 22411527.
      View in: PubMed
    29. Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa AR, Fernandes AC, Lopes-da-Costa L, Krasnoperov V, Liu R, Gill P, Duarte A. Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. PLoS One. 2012; 7(1):e29863. PMID: 22279550; PMCID: PMC3261161.
    30. Liu R, Trindade A, Sun Z, Kumar R, Weaver FA, Krasnoperov V, Naga K, Duarte A, Gill P. Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues. Biochem Biophys Res Commun. 2012 Feb 03; 418(1):173-9. PMID: 22252294.
      View in: PubMed
    31. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill P, Duarte A. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 2010 Nov 23; 10:641. PMID: 21092311; PMCID: PMC3001720.
    32. Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, Robinson LJ, Gill P, Chaudhary PM. Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol Ther. 2010 Nov 15; 10(10):1033-40. PMID: 20818173; PMCID: PMC3047095.
    33. Brar M, Cheng L, Yuson R, Mojana F, Freeman WR, Gill P. Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling. Br J Ophthalmol. 2010 Dec; 94(12):1668-73. PMID: 20934994.
      View in: PubMed
    34. Lee HR, Lee S, Chaudhary PM, Gill P, Jung JU. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Future Microbiol. 2010 Sep; 5(9):1349-65. PMID: 20860481; PMCID: PMC3076960.
    35. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill P, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88. PMID: 20682653; PMCID: PMC2933364.
    36. Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, Chaudhary PM, Jung J, Gill P. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 2010 Jul 15; 116(2):297-305. PMID: 20442363; PMCID: PMC2910613.
    37. Zhang Y, Liu R, Ni M, Gill P, Lee AS. Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. J Biol Chem. 2010 May 14; 285(20):15065-75. PMID: 20208072; PMCID: PMC2865300.
    38. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill P. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol. 2010 Apr; 176(4):2029-38. PMID: 20133814; PMCID: PMC2843490.
    39. Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill P. KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood. 2010 Jan 28; 115(4):887-95. PMID: 19965636; PMCID: PMC2815507.
    40. He S, Kumar SR, Zhou P, Krasnoperov V, Ryan SJ, Gill P, Hinton DR. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci. 2010 Jan; 51(1):543-52. PMID: 19696168; PMCID: PMC2828363.
    41. Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA, Beart RW, Singh G, Nguyen C, Kahn M, Gill P. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 2009 May 01; 69(9):3736-45. PMID: 19366806.
      View in: PubMed
    42. Benedito R, Trindade A, Hirashima M, Henrique D, da Costa LL, Rossant J, Gill P, Duarte A. Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol. 2008 Dec 16; 8:117. PMID: 19087347; PMCID: PMC2637862.
    43. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill P. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2009 Jan 01; 113(1):254-63. PMID: 18836096; PMCID: PMC2614637.
    44. Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill P, Masood R. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2008 Sep; 134(9):985-91. PMID: 18794445.
      View in: PubMed
    45. Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill P, Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 2008 Sep 01; 112(5):1720-9. PMID: 18559979; PMCID: PMC2518882.
    46. Cozen W, Gill P, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM. Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood. 2008 Apr 01; 111(7):3377-82. PMID: 18077789; PMCID: PMC2275007.
    47. Gill P. The origin of Kaposi sarcoma. J Natl Cancer Inst. 2007 Jul 18; 99(14):1063. PMID: 17623793.
      View in: PubMed
    48. Ku TK, Nguyen DC, Karaman M, Gill P, Hacia JG, Crowe DL. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res. 2007 Apr; 5(4):351-62. PMID: 17426250.
      View in: PubMed
    49. Bishop KA, Stantchev TS, Hickey AC, Khetawat D, Bossart KN, Krasnoperov V, Gill P, Feng YR, Wang L, Eaton BT, Wang LF, Broder CC. Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol. 2007 Jun; 81(11):5893-901. PMID: 17376907; PMCID: PMC1900305.
    50. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill P. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007 Jun 01; 109(11):4753-60. PMID: 17311993; PMCID: PMC1885521.
    51. Damschroder MM, Widjaja L, Gill P, Krasnoperov V, Jiang W, Dall'Acqua WF, Wu H. Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol. 2007 Apr; 44(11):3049-60. PMID: 17241664.
      View in: PubMed
    52. Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill P. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Oct; 132(10):1053-9. PMID: 17043250.
      View in: PubMed
    53. Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schönthal AH, Gill P. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer. 2006 Sep 15; 119(6):1236-48. PMID: 16615113.
      View in: PubMed
    54. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill P. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006 Jul; 169(1):279-93. PMID: 16816380; PMCID: PMC1698769.
    55. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill P. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006 Apr; 175(4):1245-52. PMID: 16515971.
      View in: PubMed
    56. Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill P. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. PMID: 16520466.
      View in: PubMed
    57. He S, Ding Y, Zhou J, Krasnoperov V, Zozulya S, Kumar SR, Ryan SJ, Gill P, Hinton DR. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2005 Dec; 46(12):4772-9. PMID: 16303978.
      View in: PubMed
    58. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill P. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 2006 Mar 15; 107(6):2330-8. PMID: 16322467; PMCID: PMC1895726.
    59. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill P. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. PMID: 15958611.
      View in: PubMed
    60. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill P. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 01; 65(11):4623-32. PMID: 15930280.
      View in: PubMed
    61. Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr; 95(6):739-42. PMID: 15794774.
      View in: PubMed
    62. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill P, Reber HA. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery. 2005 Feb; 137(2):192-9. PMID: 15674201.
      View in: PubMed
    63. Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10; 23(5):990-8. PMID: 15598977.
      View in: PubMed
    64. Cozen W, Diaz-Sanchez D, James Gauderman W, Zadnick J, Cockburn MG, Gill P, Masood R, Hamilton AS, Jyrala M, Mack TM. Th1 and Th2 cytokines and IgE levels in identical twins with varying levels of cigarette consumption. J Clin Immunol. 2004 Nov; 24(6):617-22. PMID: 15622446.
      View in: PubMed
    65. Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A, Gill P. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood. 2005 Feb 01; 105(3):1310-8. PMID: 15471957.
      View in: PubMed
    66. Frankel AE, Gill P. VEGF and myeloid leukemias. Leuk Res. 2004 Jul; 28(7):675-7. PMID: 15158088.
      View in: PubMed
    67. Wang JF, Liu ZY, Anand AR, Zhang X, Brown LF, Dezube BJ, Gill P, Ganju RK. Alpha-chemokine-mediated signal transduction in human Kaposi's sarcoma spindle cells. Biochim Biophys Acta. 2004 May 03; 1691(2-3):129-39. PMID: 15110993.
      View in: PubMed
    68. Cozen W, Gill P, Ingles SA, Masood R, Martínez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, Wang W, Gage J, Gundell-Miller S, Mack TM. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004 Apr 15; 103(8):3216-21. PMID: 15070705.
      View in: PubMed
    69. Sinha UK, Kundra A, Scalia P, Smith DL, Parsa B, Masood R, Gill P. Expression of EphB4 in head and neck squamous cell carcinoma. Ear Nose Throat J. 2003 Nov; 82(11):866, 869-70, 887. PMID: 14661437.
      View in: PubMed
    70. Smith DL, Cai J, Zhu S, Wei W, Fukumoto J, Sharma S, Masood R, Gill P. Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. Int J Cancer. 2003 Sep 10; 106(4):528-33. PMID: 12845648.
      View in: PubMed
    71. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill P. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003 May 01; 104(5):603-10. PMID: 12594815.
      View in: PubMed
    72. Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill P. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61. PMID: 12467070.
      View in: PubMed
    73. Tulpule A, Groopman J, Saville MW, Harrington W, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill P. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002 Jul 01; 95(1):147-54. PMID: 12115328.
      View in: PubMed
    74. Hotz HG, Gill P, Masood R, Hotz B, Buhr HJ, Foitzik T, Hines OJ, Reber HA. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg. 2002 Mar-Apr; 6(2):159-66; discussion 166. PMID: 11992800.
      View in: PubMed
    75. Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill P, Levine AM. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002 Feb; 26(2):121-7. PMID: 11755462.
      View in: PubMed
    76. Masood R, Cesarman E, Smith DL, Gill P, Flore O. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol. 2002 Jan; 160(1):23-9. PMID: 11786394; PMCID: PMC1867113.
    Parkash's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Related Authors
    People who share related concepts with this person.